# Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)

> **NCT06152237** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Taysha Gene Therapies, Inc.** · enrollment: 6 (actual)

## Conditions studied

- Rett Syndrome

## Interventions

- **GENETIC:** TSHA-102

## Key facts

- **NCT ID:** NCT06152237
- **Lead sponsor:** Taysha Gene Therapies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-12-12
- **Primary completion:** 2028-11-02
- **Final completion:** 2031-11-02
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06152237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06152237, "Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06152237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*